ArticleOrphanet journal of rare diseases2025
Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02638389 (Phase III Multicentric Study Evaluating the Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Multicentric Study Evaluating the Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mTOR inhibitor Sirolimus was shown to improve symptoms in patients with slow-flow vascular malformations, but long-term continuous use is limited by cumulative toxicity. A personalized approach with intermittent regimens may offer similar efficacy with fewer adverse effects (AE). This retrospective analysis evaluated the effectiveness and safety of individualized sirolimus strategies in patients who experienced symptom recurrence after completing the 2-year course in the VASE phase III trial. All patients initially resumed continuous sirolimus for 3 months, then transitioned to one personalized regimen based on their pain profiles: intermittent sirolimus 5 days-ON/2 days-OFF (Group A), hybrid intermittent plus on-demand (Group B), or fully on-demand administration triggered by pain or known stressors (Group C).
resultsThirty adults were included (Group A: n = 13; Group B: n = 6; Group C: n = 11). Across all groups, intermittent, hybrid or on-demand sirolimus maintained pain control comparable to continuous administration, significantly reducing pain intensity, crisis frequency, and crisis duration from baseline. AEs decreased from 73-85% during continuous therapy to 9-33% with intermittent/on-demand regimens, with no reported grade ≥3 event.
conclusionPersonalized intermittent sirolimus regimens may effectively control symptoms and substantially reduce toxicity in patients with vascular malformations. This strategy supports individualized, long-term therapy and merits prospective validation.
trial registrationNCT02638389 and EudraCT 2015-001703-32.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.